Healthcare Consulting China
WE REALIZE YOUR CHINA-RELATED
SILREAL offers a wide range of consulting services with the ultimate goal of supporting European companies expand in Chinese markets and vice-versa. Working with our clients from start to finish, we help develop new ideas, define effective strategies and implement sustainable solutions.
SILREAL leverages its profound cultural and economic expertise with its extensive network of top decision-makers in China to create a business-friendly bridge from Europe to the Middle Kingdom. A holistic consulting approach within the healthcare market in China guides our work from planning to implementation, resulting in measurable success for our clients in their international business.
Our mission is to advance the cooperation between the healthcare systems of the
DACH region and China
Opportunities of the Chinese healthcare market
3 trends make entering the Chinese healthcare market invaluable
IMPORTANCE OF HEALTH
Health expenditure in China doubled in 2018 compared to 2010 to €256 per capita. Due to the persistently high NCD* mortality, these expenses will tend to increase. An increase in the life expectancy of the Chinese population from 44 years to 77 years in the last 60 years shows the importance of the flourishing health sector.
China has one of the most advanced digital ecosystems in the world, with more than 800 million active internet users. Together with an increase in the use of digital health platforms and rapidly increasing annual sales in the medical technology sector, the Chinese healthcare market offers attractive entry opportunities.
The "Healthy China 2030" and "Made in China 2025" political strategies are seen as drivers of the improvement in the Chinese healthcare sector. These lead to an improvement in the quality of services, to the reform of the pharmaceutical and medical product systems and to a focus on the production of pharmaceutical high-tech products.
* NCD = Non-Communicable Diseases
3 common problems that prevent companies from profiting from the Chinese market:
Challenges of the Chinese healthcare market
Frequent regulatory changes are a headache for most German companies. Increasing efforts by the Chinese government to manufacture medical devices in China and the 4 + 7 policy make it difficult for German companies to establish themselves in the Chinese market.
LIMITED MARKET ACCESS
Entry into the Chinese market is made difficult by unclear standards for medical devices and drugs. There are also industry-specific regulations for foreign companies. Foreign direct investments in medical facilities are often only possible with a large participation of Chinese partners.
LACK OF EXPERTISE
German companies in China have difficulties in obtaining licenses or product approvals. The high bureaucratic effort, the legal uncertainty and the unclear regulatory framework are some of the greatest challenges for German companies in China.
OUR CONSULTING APPROACH
... for your entry into the healthcare market in China
... complements our in-depth knowledge of the Chinese healthcare system
... are part of our approach and setting us apart from generic consulting
... on the healthcare system and China ensure high-quality advice
We enable and support your China-related plans
Providing profound understanding of the Chinese healthcare ecosystem
Continuous market monitoring and close exchange with key opinion leaders and policy-makers
Identification of relevant partners, important decision makers and political contacts
Development of customized business plans using an extensive, high-level network and China-based consultants
Identification of business and growth opportunities in the relevant health care segments
Initiation of partnerships with relevant companies and organizations
Management of license and certification process
Management of supply chains and regulatory compliance
OUR SUCCESS STORY
A selection of our previous projects:
Implementation of a time-to-market strategy on behalf of a Chinese MedTech company in the field of dermatology.
Analysis of marketability
Analysis of an OTC drug for the treatment of mouth and throat infections on behalf of a German pharmaceutical company as well as the investigation of market access requirements.
Execution of a go-to-market analysis on behalf of a leading global insurance company.
Digital Health China Pitch
Analysis of the Chinese digital health market and conception of market entry strategies for a digital health service provider on behalf of a leading international pharmaceutical company.